PAHC (Phibro Animal Health) NonCurrent Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAHC Phibro Animal Health Corp PAHC
70 GF Score
Price $38.59
GF Value $31.34
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Phibro Animal Health NonCurrent Deferred Revenue?

Phibro Animal Health PAHC -3.36% 70 NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates PAHC with a GF Score™ of 70/100 and a GF Value™ of $31.34 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Phibro Animal Health's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

Phibro Animal Health NonCurrent Deferred Revenue Related Terms

Phibro Animal Health NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Phibro Animal Health's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phibro Animal Health NonCurrent Deferred Revenue Chart

Phibro Animal Health Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Phibro Animal Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PAHC
70GF Score
Phibro Animal Health Corp PAHC
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
Phibro Animal Health (PAHC) has a NonCurrent Deferred Revenue of $0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Phibro Animal Health and its competitors.
Is Phibro Animal Health's NonCurrent Deferred Revenue too high?
Phibro Animal Health's current NonCurrent Deferred Revenue is $0 Mil. Overall, Phibro Animal Health has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's NonCurrent Deferred Revenue compare to XERS and HROW?
Phibro Animal Health's NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Phibro Animal Health and its competitors. Phibro Animal Health's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $31.34, compared to a current price of $38.59 — trading 23.1% above its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. Phibro Animal Health's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phibro Animal Health (PAHC) Overvalued in 2026?

Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued. The current stock price of $38.59 is trading 23.1% above its estimated GF Value™ of $31.34. GuruFocus considers Phibro Animal Health to be Modestly Overvalued.

Key valuation signals for PAHC:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $31.34 vs. price of $38.59 (23.1% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phibro Animal Health Business Description

Other Exchanges PB8:Germany
Address 300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
70GF Score

Get the complete analysis for PAHC

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.59
Price
$31.34
GF Value